Log In
Print
BCIQ
Print
Print this Print this
 

Lazanda (PecFent) (formerly NasalFent)

  Manage Alerts
Collapse Summary General Information
Company Kyowa Hakko Kirin Co. Ltd.
DescriptionFentanyl citrate nasal spray
Molecular Target Opioid receptor (OPR)
Mechanism of ActionOpioid receptor agonist
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentMarketed
Standard IndicationPain
Indication DetailsTreat breakthrough cancer pain
Regulatory Designation
Partner Depomed Inc.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

3

$2,214.4M

$2,198.4M

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone
Get a free BioCentury trial today